Mumbai: India has two such vaccines to be given so far which are proving to be helpful in preventing corona, but now such a vaccine is being developed which targets Omicron variants. In fact, this vaccine has also been prepared. But it is waiting to be approved. It is believed that this vaccine, which has been prepared on the mRNA platform, will prove to be a big achievement for the country.
According to reports, the new indigenous vaccine is coming soon on the new variant of Corona, Omicron, which will be very effective to get rid of Omicron. It is worth noting that after the Delta variant, the Omicron variant has wreaked havoc all over the world as it is spreading very fast and it is affecting all those who survived in the first two waves till now.
Data sent to central government
According to the information, a Pune-based pharmaceutical company is preparing this vaccine to deal with this rapidly spreading variant from Delta. The research of this company named Genova Biopharmaceutical has reached its third stage and this company has prepared the mRNA vaccine and is just waiting for its approval. The data of the second phase of research of this indigenous vaccine, prepared to keep in mind the international standards, has been given to the regulatory body of the central government. Now this company is awaiting approval from the Subject Expert Committee of the Drugs Controller General of India. This organization will soon review the formula prepared by the company and give its approval.
Testing of two doses on 3,000 people
This mRNA vaccine has been developed for the Delta variant of the SARS Covid-2 virus and during the second phase of research, its two doses have been tested on 3,000 people. Now the third phase of testing is about to start. At present, the company has started its production only. Once the approval is received, the full production will be able to start.
The vaccine will prove to be a big achievement for the country
At present, the company is not producing it rapidly because it threatens to spoil the vaccine. So we are waiting for approval. It is believed that after getting approval, this vaccine, which has been prepared on the mRNA platform, will prove to be a big achievement for the country. After this, the company also has a vaccine directly targeting Omicron. If it is approved first, then its testing will also be started.
How does this vaccine work?
Messenger RNA or mRNA technology involves introducing a small part of the virus’s genetic code (RNA) into the body to enhance the immune response. These mimic a part of the coronavirus and activate the immune system. The vaccine does not contain any actual virus. Genova, in collaboration with HDT Biotech Corporation of the US, has developed the mRNA vaccine (AGCO19), which has proven to be safe, capable of antibody neutralization in rodent and non-human models.
